博雅生物
(300294)
| 流通市值：137.21亿 | | | 总市值：137.21亿 |
| 流通股本：5.04亿 | | | 总股本：5.04亿 |
| 报告期 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,734,904,402.71 | 1,245,107,779.6 | 895,735,666.55 | 448,452,537.26 |
| 营业收入 | 1,734,904,402.71 | 1,245,107,779.6 | 895,735,666.55 | 448,452,537.26 |
| 二、营业总成本 | 1,279,267,786.34 | 853,438,255.57 | 590,060,239.82 | 301,267,242.96 |
| 营业成本 | 613,214,874.16 | 415,047,987.13 | 295,361,445.36 | 144,457,836.4 |
| 税金及附加 | 18,483,761.64 | 12,960,180.36 | 8,020,971.78 | 4,016,540.27 |
| 销售费用 | 419,587,310.64 | 273,785,234.14 | 192,731,269.38 | 104,036,460.15 |
| 管理费用 | 186,665,698.91 | 127,759,054.31 | 80,666,785.32 | 37,957,181.42 |
| 研发费用 | 66,889,890.67 | 47,378,915.31 | 30,323,589.35 | 19,006,039.85 |
| 财务费用 | -25,573,749.68 | -23,493,115.68 | -17,043,821.37 | -8,206,815.13 |
| 其中:利息费用 | 664,233.66 | 125,070.13 | 104,472.44 | 18,610.32 |
| 其中:利息收入 | 29,430,779.84 | 23,873,998.69 | 17,317,447.97 | 8,270,480.83 |
| 加:公允价值变动收益 | 65,582,550.87 | 60,816,469.74 | 39,088,022.83 | 18,515,926.66 |
| 加:投资收益 | 13,061,606.76 | 7,811,944.55 | 6,709,830.32 | 1,191,885.1 |
| 资产处置收益 | -611,748.07 | -302,546.14 | -125,108.14 | - |
| 资产减值损失(新) | -83,825,238.02 | 628,571.77 | -196,478.4 | 660,313.48 |
| 信用减值损失(新) | -7,495,696.91 | -2,906,848.49 | -5,830,411.4 | -1,685,231.72 |
| 其他收益 | 34,906,649.43 | 22,587,554.44 | 21,250,412.03 | 8,880,607.49 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 477,254,740.43 | 480,304,669.9 | 366,571,693.97 | 174,748,795.31 |
| 加:营业外收入 | 6,883,629.91 | 5,986,732.7 | 5,157,397.92 | 1,594,051.4 |
| 减:营业外支出 | 6,424,817.25 | 5,866,127.73 | 3,879,495.21 | 68,871.54 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 477,713,553.09 | 480,425,274.87 | 367,849,596.68 | 176,273,975.17 |
| 减:所得税费用 | 81,185,061.68 | 67,992,997.01 | 52,146,631.24 | 24,513,132.74 |
| 六、净利润 | 396,528,491.41 | 412,432,277.86 | 315,702,965.44 | 151,760,842.43 |
| 持续经营净利润 | 396,528,491.41 | 412,432,277.86 | 315,702,965.44 | 151,760,842.43 |
| 归属于母公司股东的净利润 | 396,991,588.69 | 412,703,629.27 | 315,970,311.01 | 152,024,886.81 |
| 少数股东损益 | -463,097.28 | -271,351.41 | -267,345.57 | -264,044.38 |
| (一)基本每股收益 | 0.79 | 0.82 | 0.63 | 0.3 |
| (二)稀释每股收益 | 0.79 | 0.82 | 0.63 | 0.3 |
| 八、其他综合收益 | 2,363,203.42 | - | - | - |
| 归属于母公司股东的其他综合收益 | 2,363,203.42 | - | - | - |
| 九、综合收益总额 | 398,891,694.83 | 412,432,277.86 | 315,702,965.44 | 151,760,842.43 |
| 归属于母公司股东的综合收益总额 | 399,354,792.11 | 412,703,629.27 | 315,970,311.01 | 152,024,886.81 |
| 归属于少数股东的综合收益总额 | -463,097.28 | -271,351.41 | -267,345.57 | -264,044.38 |
| 公告日期 | 2025-03-19 | 2024-10-25 | 2024-08-24 | 2024-04-24 |
| 审计意见(境内) | 标准无保留意见 | | | |